Evaluating Total Ablative Therapy Plus Standard Chemotherapy Versus Standard Chemotherapy Alone for Limited Metastatic Colorectal Cancer in a Randomized Phase II Trial
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
146
Participants Needed
195
Research Sites
214 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding total ablative therapy TAT to the usual systemic treatment improves outcomes for patients with advanced colorectal cancer that has spread to up to four body sites. The study compares this combined approach to systemic therapy alone in patients newly diagnosed with limited metastatic colorectal cancer. This phase II trial aims to assess overall survival and other important outcomes while monitoring side effects.
Participants are randomly assigned to one of two groups. One group receives total ablative therapy, which may include stereotactic ablative radiotherapy SABR, surgical removal of tumors, or microwave ablation, along with standard chemotherapy. The other group receives only the standard chemotherapy. Throughout the trial, patients undergo imaging scans like CT, MRI, or PETCT and may have endoscopic exams and optional blood sample collections. After treatment, patients are followed for up to five years.
During the trial, participants have regular scans to monitor the cancers status and any recurrence. Researchers evaluate overall survival from the time of randomization and track event-free survival, adverse events, and time to local recurrence in the group receiving ablative therapy. The study includes detailed assessments to understand treatment effects and safety over a long-term follow-up period, lasting up to five years after registration.
CONDITIONS
Brief Title
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Research Team
E
Eric D. Miller, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
TAT + Chemotherapy
Chemotherapy Alone
What this involves
Combination of stereotactic ablative radiotherapy, surgical resection, and/or microwave ablation added to standard systemic chemotherapy.
Standard‑of‑care systemic chemotherapy without addition of ablative local therapies.
Role in trial
Investigational treatment arm combining local ablative therapy with systemic chemotherapy.
Active comparator arm using systemic chemotherapy alone.
Purpose
To assess whether adding local ablative therapies to systemic chemotherapy improves overall survival and other outcomes in patients with oligometastatic colorectal cancer.
To serve as reference comparison for survival and progression outcomes with chemotherapy alone.
How treatment is given
Systemic chemotherapy per standard of care plus one or more local ablative treatments (SABR, surgical resection, or microwave ablation) delivered according to protocol.
Systemic chemotherapy alone as defined by standard‑of‑care regimens.
Supporting evidence
Randomized phase III trial currently recruiting; efficacy yet to be established.
Systemic chemotherapy alone prolongs survival in metastatic colorectal cancer and serves as standard practice.
Limitations
Effectiveness and safety are not yet known until trial results are available.
Does not include local ablative treatment, which may offer benefit in selected oligometastatic patients.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Women and men of reproductive potential must agree to use effective birth control during the study
Diagnosed with metastatic colorectal adenocarcinoma confirmed by biopsy
No known microsatellite instable (MSI) tumor or BRAF V600E mutation
Treated brain metastases allowed if stable on follow-up imaging
No peritoneal or omental metastases confirmed by imaging or laparoscopy if suspected
Liver-only metastatic disease on baseline imaging is not allowed unless another metastatic site is present
Measurable disease per RECIST version 1.1 required
Cardiac function assessed as New York Heart Association class 2B or better
Prior or concurrent malignancies allowed if they don't interfere with study assessments
Primary tumor must be resected, have clinical complete response without regrowth, or be surgically resectable
Four or fewer metastatic sites amenable to surgery, SABR, or microwave ablation
Receiving or have received first-line systemic therapy for metastatic disease for 12 to 52 weeks
Prior definitive therapy completed at least 6 months before metastatic diagnosis
Not pregnant or nursing with negative pregnancy test if female of childbearing potential
Age 18 years or older
ECOG performance status 0-2
Adequate blood counts and organ function including neutrophils, platelets, creatinine clearance, bilirubin, and liver enzymes
HIV-infected patients on effective therapy with undetectable viral load eligible
No other investigational agents planned concurrently on study
You will not qualify if you...
N/A
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 52 weeks
Participants receive either total ablative therapy combined with standard chemotherapy or standard chemotherapy alone. They undergo imaging scans like CT, MRI, or PET/CT and may have endoscopic exams and blood tests during this phase.
Regular imaging and clinical assessments during treatment
Follow-up
Duration - 5 years
After treatment, participants are followed for up to 5 years to monitor overall survival and disease progression with periodic assessments.
Periodic follow-up visits and scans
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 1 Study to Evaluate Safety and Effects of PF-08032562 Alone or with Other Cancer Treatments in Advanced or Metastatic Breast and Colorectal Cancer
Phase 2 Study of Adding Amplitude-Modulated Radiofrequency Electromagnetic Fields Device to Fruquintinib for Treatment-Resistant Metastatic Colorectal Cancer
Evaluating a New MRI Scan to Measure Treatment Response in Patients With Colorectal Cancer That Has Spread to the Liver
Phase 2 Study of Avapritinib for Adults With CKIT or PDGFRA Mutation-Positive Advanced or Metastatic Malignant Solid Tumors
Phase 1b Study of Botensilimab and Balstilimab with Fasting-Mimicking Diet and Vitamin C for Adults with KRAS-Mutant Metastatic Colorectal Cancer
Phase I Study of CA-4948 Combined With FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer
Pilot Trial Comparing In-Home Versus In-Clinic Subcutaneous Nivolumab Administration
for Cancer Care Through the Connected Access and Remote Expertise CARE Beyond Walls CCBW Program
Phase 2 Study of Devimistat with Hydroxychloroquine and 5-Fluorouracil or Gemcitabine
for Advanced Chemotherapy-Resistant Solid Tumors Including Colorectal, Pancreatic, and Others
Comparing Cryoablation Plus Stereotactic Body Radiation Therapy to Radiation Therapy Alone
for Pain Relief in Patients with Painful Bone Metastases
Phase 12 Study of Dual-Target CAR-NK Cell Therapy for Adults with Advanced or Metastatic Colorectal Cancer
Targeting CEA, GUCY2C, and HER2 Antigens
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur).